Aurinia Pharmaceuticals Inc
AUPH7.300USD
-0.180-2.41%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.01BValor de mercado
25.24P/L TTM
Mais detalhes de Aurinia Pharmaceuticals Inc Empresa
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.
Informações da empresa
Código da empresaAUPH
Nome da EmpresaAurinia Pharmaceuticals Inc
Data de listagemJul 16, 2001
Fundado em2009
CEOMr. Peter S. Greenleaf
Número de funcionários130
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 16
Endereço#140, 14315 - 118 Avenue
CidadeEDMONTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCanada
Código postalT5L 4S6
Telefone12507442487
Sitehttps://www.auriniapharma.com
Código da empresaAUPH
Data de listagemJul 16, 2001
Fundado em2009
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Dr. Karen Lesley Smith, M.D., Ph.D.
Dr. Karen Lesley Smith, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin Tang
Mr. Kevin Tang
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. David R.W Jayne, M.D.
Dr. David R.W Jayne, M.D.
Independent Director
Independent Director
--
--
Mr. Craig Johnson
Mr. Craig Johnson
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Peter S. Greenleaf
Mr. Peter S. Greenleaf
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
667.87K
+16.06%
Mr. Stephen P. Robertson
Mr. Stephen P. Robertson
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
176.21K
+23.75%
Ms. Jill Diane Leversage
Ms. Jill Diane Leversage
Independent Director
Independent Director
12.92K
-17.94%
Dr. Greg Keenan
Dr. Greg Keenan
Chief Medical Officer
Chief Medical Officer
10.51K
-93.15%
Mr. Joseph Miller
Mr. Joseph Miller
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Andrea Christopher
Ms. Andrea Christopher
Executive Director, Corporate Communications and Investor Relations
Executive Director, Corporate Communications and Investor Relations
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 30 de jun
Moeda: USDAtualizado em: seg, 30 de jun
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
US
210.09M
89.35%
Japan
25.04M
10.65%
Other
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 16 horas
Atualizado em: há 16 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Investidores
Investidores
Proporção
Tang Capital Management, LLC
7.42%
ILJIN SNT Co., Ltd.
6.57%
BlackRock Institutional Trust Company, N.A.
5.53%
Armistice Capital LLC
3.70%
New Enterprise Associates (NEA)
2.94%
Other
73.84%
Tipos de investidores
Investidores
Proporção
Hedge Fund
14.35%
Investment Advisor
12.78%
Investment Advisor/Hedge Fund
12.71%
Corporation
6.57%
Venture Capital
3.02%
Research Firm
2.96%
Individual Investor
2.80%
Pension Fund
0.52%
Bank and Trust
0.35%
Other
43.95%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
436
77.25M
57.17%
-345.00
2025Q1
457
75.49M
55.51%
-3.25M
2024Q4
454
71.04M
51.53%
-9.95M
2024Q3
449
70.86M
49.85%
-8.98M
2024Q2
452
69.33M
48.80%
-9.83M
2024Q1
446
69.12M
48.16%
-8.26M
2023Q4
460
67.04M
46.69%
-7.24M
2023Q3
469
63.17M
44.06%
-14.31M
2023Q2
493
65.34M
45.61%
-23.55M
2023Q1
499
65.33M
45.73%
-27.23M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Tang Capital Management, LLC
10.03M
7.42%
+1.60M
+18.98%
Mar 31, 2025
ILJIN SNT Co., Ltd.
8.88M
6.57%
+2.48M
+38.78%
Apr 12, 2025
BlackRock Institutional Trust Company, N.A.
7.47M
5.53%
-150.03K
-1.97%
Mar 31, 2025
Armistice Capital LLC
5.00M
3.7%
-1.40M
-21.88%
Mar 31, 2025
New Enterprise Associates (NEA)
3.97M
2.94%
--
--
Mar 31, 2025
State Street Global Advisors (US)
2.85M
2.11%
-66.87K
-2.29%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.44%
+241.86K
+14.20%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
1.29%
+754.77K
+76.56%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.73M
1.28%
-30.09K
-1.71%
Mar 31, 2025
Arrowstreet Capital, Limited Partnership
1.64M
1.21%
+564.52K
+52.47%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 8 horas
Atualizado em: há 8 horas
Nome
Proporção
Virtus LifeSci Biotech Products ETF
1.48%
ALPS Medical Breakthroughs ETF
0.93%
Janus Henderson Small Cap Growth Alpha ETF
0.7%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.12%
Vanguard US Momentum Factor ETF
0.1%
iShares Biotechnology ETF
0.1%
Vanguard US Multifactor ETF
0.1%
Avantis US Small Cap Equity ETF
0.09%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção1.48%
ALPS Medical Breakthroughs ETF
Proporção0.93%
Janus Henderson Small Cap Growth Alpha ETF
Proporção0.7%
SPDR S&P International Small Cap ETF
Proporção0.14%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
ProShares Ultra Nasdaq Biotechnology
Proporção0.12%
Vanguard US Momentum Factor ETF
Proporção0.1%
iShares Biotechnology ETF
Proporção0.1%
Vanguard US Multifactor ETF
Proporção0.1%
Avantis US Small Cap Equity ETF
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
